For the first time in a decade, adult obesity in the United States dropped last year, a new study has found, and researchers are curious how the rise in popularity of weight loss drugs like Ozempic may have played a role. Published in JAMA Health Forum on ...

In a public health breakthrough, U.S. obesity rates have decreased for the first time in more than a decade, with new weight loss medications potentially playing a role in the turnaround, according to a new study.

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like Ozempic and Wegovy, according to the study authors.

Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has seen a downward trend. That might be due, in part, to the recent rise of blockbuster weight loss drugs like Ozempic, according to the study authors.

The obesity rate among US adults declined in 2023 for the first time in over a decade, as per a study published in the JAMA Health Forum.

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.

A new study shows that obesity rates in U.S. adults are falling for the first time in a decade. It's good sign for health and healthcare costs because losing weight can help reduce the risk of serious illnesses like Type 2 diabetes and certain kinds of cancer.

A new study reveals a slight drop in U.S. obesity rates, driven by weight loss drugs, lifestyle changes post-COVID, and regional trends. Experts caution that long-term impacts remain uncertain despite this encouraging sign.

For the first time in over a decade, American adults made strides to become healthier in 2023, as the obesity rates have fallen, according to a new study.